Vericel (NASDAQ:VCEL) – Investment analysts at Leerink Swann issued their Q1 2018 earnings per share (EPS) estimates for Vericel in a report released on Wednesday, April 4th. Leerink Swann analyst D. Antalffy anticipates that the biotechnology company will earn ($0.12) per share for the quarter. Leerink Swann currently has a “Outperform” rating and a $15.00 target price on the stock. Leerink Swann also issued estimates for Vericel’s Q2 2018 earnings at ($0.05) EPS, Q3 2018 earnings at ($0.09) EPS, Q4 2018 earnings at $0.02 EPS, FY2018 earnings at ($0.24) EPS, Q1 2019 earnings at ($0.08) EPS, Q2 2019 earnings at $0.00 EPS, Q3 2019 earnings at ($0.05) EPS, Q4 2019 earnings at $0.08 EPS, FY2019 earnings at ($0.05) EPS, FY2020 earnings at $0.11 EPS, FY2021 earnings at $0.32 EPS and FY2022 earnings at $0.50 EPS.
Vericel (NASDAQ:VCEL) last announced its quarterly earnings results on Monday, March 5th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.13. The company had revenue of $23.35 million for the quarter. Vericel had a negative net margin of 27.04% and a negative return on equity of 98.77%.
Shares of NASDAQ VCEL opened at $11.20 on Friday. Vericel has a 52-week low of $2.35 and a 52-week high of $12.80. The firm has a market capitalization of $406.30, a price-to-earnings ratio of -22.40 and a beta of 3.18. The company has a debt-to-equity ratio of 0.75, a quick ratio of 3.57 and a current ratio of 3.86.
Several large investors have recently modified their holdings of the business. Bank of New York Mellon Corp grew its stake in shares of Vericel by 35.2% in the 4th quarter. Bank of New York Mellon Corp now owns 44,188 shares of the biotechnology company’s stock worth $241,000 after buying an additional 11,509 shares in the last quarter. Perkins Capital Management Inc. grew its stake in shares of Vericel by 2.9% in the 4th quarter. Perkins Capital Management Inc. now owns 578,950 shares of the biotechnology company’s stock worth $3,155,000 after buying an additional 16,350 shares in the last quarter. Goldman Sachs Group Inc. purchased a new position in shares of Vericel in the 4th quarter worth $105,000. Bank of Montreal Can purchased a new position in shares of Vericel in the 4th quarter worth $140,000. Finally, Geode Capital Management LLC grew its stake in shares of Vericel by 11.9% in the 4th quarter. Geode Capital Management LLC now owns 255,168 shares of the biotechnology company’s stock worth $1,390,000 after buying an additional 27,226 shares in the last quarter. 37.22% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This news story was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/3336730/vericel-to-post-q1-2018-earnings-of-0-12-per-share-leerink-swann-forecasts-vcel.html.
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States.
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.